Published in J Immunother Cancer on December 16, 2014
Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664
Early Detection of Four Common Cancers Using the ctDNA Analysing Test (K-DETEK) | NCT05227261
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget (2015) 1.12
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep (2015) 1.04
Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci (2015) 0.90
Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer (2017) 0.88
Sensitivity of plasma BRAF(mutant) and NRAS(mutant) cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol Oncol (2015) 0.87
Ovarian cancer treatment: The end of empiricism? Cancer (2015) 0.85
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget (2016) 0.85
Cell-free circulating tumor DNA in cancer. Chin J Cancer (2016) 0.85
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Sci Rep (2016) 0.83
Immunomodulation: checkpoint blockade etc. Neuro Oncol (2015) 0.78
Revisiting determinants of prognosis in cutaneous melanoma. Cancer (2015) 0.77
Rapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report. Am J Case Rep (2017) 0.76
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early Time-Point FDG-PET/CT Imaging in Patients with Advanced Melanoma. J Nucl Med (2017) 0.76
Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. Oncologist (2015) 0.75
Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer (2016) 0.75
Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. Respir Med Case Rep (2017) 0.75
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. Eur J Nucl Med Mol Imaging (2017) 0.75
Concerning the article by Louveau et al "Clinical value of early detection of circulating tumour DNA BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor". ESMO Open (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods (2006) 4.21
Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med (2012) 3.92
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res (2009) 3.01
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst (2014) 2.29
Prognosis of patients with transected melanomas. Dermatol Surg (2013) 2.04
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov (2014) 1.77
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun (2008) 1.75
Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma. Am J Surg (2013) 0.79
The rate of melanoma transection with various biopsy techniques and the influence of tumor transection on patient survival. J Am Acad Dermatol (2012) 0.79